FOUNDATIONONE®CDx

PATIENT
Lin Chung, Shu Ying

TUMOR TYPE
Skin melanoma

COUNTRY CODE
TW

REPORT DATE
20 Jun 2023

ORDERED TEST #
ORD-1648390-01

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT
DISEASE Skin melanoma
NAME Lin Chung, Shu Ying
DATE OF BIRTH 20 April 1952
SEX Female
MEDICAL RECORD # 7948825

PHYSICIAN
ORDERING PHYSICIAN Yeh, Yi-Chen
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN
SPECIMEN SITE Lymph Node
SPECIMEN ID S112-25343 G (PF23078)
SPECIMEN TYPE Slide Deck
DATE OF COLLECTION 31 May 2023
SPECIMEN RECEIVED 09 June 2023

Biomarker Findings

Microsatellite status - MS-Stable
Tumor Mutational Burden - 1 Muts/Mb

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

NRAS Q61R
MUTYH splice site 892-2A>G
PRDM1 V10fs*10
SGK1 loss exons 1-12
SMAD2 loss exons 7-8
TERT promoter -146C>T

2 Disease relevant genes with no reportable alterations: ***BRAF, KIT***

Report Highlights

- Targeted therapies with potential clinical benefit **approved in this patient's tumor type: Trametinib** (p. 7)
- Evidence-matched **clinical trial options** based on this patient's genomic findings: (p. 9)
- Variants in select cancer susceptibility genes to consider for possible **follow-up germline testing** in the appropriate clinical context: ***MUTYH* splice site 892-2A>G** (p. 4)

BIOMARKER FINDINGS

Microsatellite status - MS-Stable

Tumor Mutational Burden - 1 Muts/Mb

GENOMIC FINDINGS

***NRAS* -** Q61R

10 Trials see p. 9

THERAPY AND CLINICAL TRIAL IMPLICATIONS

No therapies or clinical trials. See Biomarker Findings section

No therapies or clinical trials. See Biomarker Findings section

THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)
Trametinib	Cobimetinib
	Selumetinib

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING IN SELECT CANCER SUSCEPTIBILITY GENES

Findings below have been previously reported as pathogenic germline in the ClinVar genomic database and were detected at an allele frequency of >10%. See appendix for details.

***MUTYH* -** splice site 892-2A>G ..... p. 4

This report does not indicate whether variants listed above are germline or somatic in this patient. In the appropriate clinical context, follow-up germline testing would be needed to determine whether a finding is germline or somatic.

Electronically signed by Erik Williams, M.D. | 20 June 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved by the US FDA.

BIOMARKER

Microsatellite status

RESULT
MS-Stable

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors[1-3], including approved therapies nivolumab and pembrolizumab[4]. In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, p=0.001)[5].

FREQUENCY & PROGNOSIS

MSI has been detected in 16-32% of cutaneous melanomas in several small datasets, with the majority exhibiting MSI-low[6]. A higher frequency of MSI (low and high) has been reported in metastatic tumors (20-77%) compared to primary tumors (2-30%)[7]. No association between MSI status and clinicopathological features of patients with melanoma was reported in one study[8].

FINDING SUMMARY

Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor[9]. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2[9-11]. This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers[12-14]. MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins[9,11,13-14].

BIOMARKER

Tumor Mutational Burden

RESULT
1 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[15-17], anti-PD-1 therapies[15-18], and combination nivolumab and ipilimumab[19-24]. In multiple studies of immune checkpoint inhibitors in melanoma, higher TMB has corresponded with clinical benefit from treatment with anti-PD-1 or anti-PD-L1 treatments[18,25-26]. Increased TMB has been associated with longer PFS and OS for patients with melanoma treated with nivolumab, with studies reporting increased benefit for patients with a mutational load above 162 missense mutations per tumor (~equivalency >8 Muts/Mb as measured by this assay)[27]. Increased TMB (~equivalency >10.8 Muts/Mb as measured by this assay) has also been associated with longer PFS and OS for patients with melanoma treated with combination nivolumab and ipilumumab[27]. Improved PFS and OS of patients with melanoma treated with ipilumumab has been observed across all TMB levels[28].

FREQUENCY & PROGNOSIS

A large-scale genomic analysis found that various melanoma subtypes harbored median TMBs between 6.3 and 14.4 Muts/Mb, and 25% to 40% of cases had elevated TMBs of greater than 20 Muts/Mb[29]. Malignant melanoma has been reported to have a high prevalence of somatic mutations compared with other tumor types[30], with desmoplastic melanoma ranking among the highest of melanoma subtypes (median TMB of 62 Muts/Mb)[31]. Higher mutational load has been reported in NF1-mutant melanoma samples compared with BRAF-mutant, NRAS-mutant, or BRAF/NRAS/NF1 wild-type samples[25]. In 1 study, elevated TMB correlated with PD-L1 positive status and increased OS in tissue specimens from patients with Stage 3 melanoma[32]. In another study, elevated tissue TMB (>20 Muts/Mb) was associated with longer PFS and OS in patients treated with anti-PD-1 or anti-PD-L1 immunotherapy as compared with patients with lower TMB[25]. Increased TMB has also been associated with histologic stage and cumulative sun exposure[33].

FINDING SUMMARY

Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[34-35] and cigarette smoke in lung cancer[36-37], treatment with temozolomide-based chemotherapy in glioma[38-39], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[40-44], and microsatellite instability (MSI)[40,43-44]. This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents[15-16,18,25,45-48].

GENE
NRAS

ALTERATION
Q61R

HGVS VARIANT
NM_002524.3:c.182A>G (p.Q61R)

VARIANT CHROMOSOMAL POSITION
chr1:115256529

VARIANT ALLELE FREQUENCY (% VAF)
16.4%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in hematologic malignancies[49-55] and solid tumors[49,56-58], NRAS activating alterations may predict sensitivity to MEK inhibitors, such as trametinib, cobimetinib, binimetinib, and selumetinib. A Phase 3 study of the MEK inhibitor binimetinib in patients with NRAS-mutated melanoma who were previously untreated or had progressed on immunotherapy reported a significant increase in median progression-free survival as compared to dacarbazine (2.8 vs. 1.5 months)[56]. In a nonrandomized Phase 2 study of binimetinib in 30 patients with NRAS-mutated melanoma, 20% (6/30) had a PR and 63% (19/30) had an SD, and the size of brain metastases was reduced in 2 patients treated with binimetinib[57]. A Phase 1 study of the ERK1/2 inhibitor ulixertinib reported PRs in 18% (3/17) and SDs in 35% (6/17) of patients with NRAS-mutated melanoma[59]. In a Phase 1 study, patients with NRAS-mutated melanoma benefited from treatment with belvarafenib, a type-II RAF inhibitor, with PRs reported in the dose-escalation (44% [4/9]) and dose-expansion (20% [2/10]) cohorts[60]. Retrospective analysis of patients with melanoma treated with first-line nivolumab plus ipilimumab showed significantly improved survival for those with BRAF-mutated disease (9.9 months median PFS [mPFS] and median OS [mOS] not reached) relative to those with either NRAS-mutated disease (4.8 months mPFS and 14.2 months mOS) or disease lacking BRAF and NRAS mutations (5.3 months mPFS and 16.1 months mOS)[61]. In a Phase 1 study evaluating the MEK-pan-RAF dual inhibitor CH5126766, 1 patient harboring an NRAS mutation experienced a PR[62].

FREQUENCY & PROGNOSIS

NRAS mutations have been reported in ~20% of melanoma cases (7-33% in various studies), with similar frequency in primary and metastatic samples[63-72]. Similar frequencies of NRAS mutations have been reported in cutaneous melanoma, mucosal melanoma, acral lentiginous melanoma (ALM), conjunctival melanoma, vulvar melanoma, vaginal melanoma and melanoma of unknown primary[63-64,73-79]. Conflicting findings have been reported regarding the prognostic significance of NRAS mutation in the context of melanoma, with some studies noting significant adverse impact on clinico-pathological features as well as overall and/or melanoma-free survival[73,79-83], whereas other studies reported no significant impact on survival[71,75,84-87].

FINDING SUMMARY

NRAS encodes a member of the RAS family of small GTPases that mediate transduction of growth signals. Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF-MAPK-ERK, PI3K, and other pathways[67]. NRAS alterations affecting amino acids G12, G13, G60, Q61, as well as mutations I24N, T50I, T58I, and A146T have been characterized as activating and oncogenic[67,88-103].

GENE
MUTYH

ALTERATION
splice site 892-2A>G

HGVS VARIANT
NM_001048171.1:c.892-2A>G (p.?)

VARIANT CHROMOSOMAL POSITION
chr1:45797760

VARIANT ALLELE FREQUENCY (% VAF)
39.8%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no therapies or clinical trials available to address MUTYH alterations in cancer.

FREQUENCY & PROGNOSIS

In general, somatic MUTYH mutations are infrequently reported across cancer types (COSMIC, 2023)[104]. Monoallelic MUTYH mutation occurs in 1-2% of the general population[105-106]. There are conflicting data regarding the impact of monoallelic mutations on the risk of developing colorectal cancer (CRC)[107-109]. Patients with MUTYH-mutated CRC were reported to have significantly improved OS compared with patients without MUTYH mutation[110].

FINDING SUMMARY

MUTYH (also known as MYH) encodes an enzyme involved in DNA base excision repair, and loss of function mutations in MUTYH result in increased rates of mutagenesis and promotion of tumorigenesis[111]. The two most frequently reported MUTYH loss of function mutations are G382D (also referred to as G396D) and Y165C (also referred to as Y179C)[105-106,112-114]. Numerous other MUTYH mutations have also been shown to result in loss of function[112-115].

POTENTIAL GERMLINE IMPLICATIONS

One or more of the MUTYH variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with MUTYH-associated polyposis (ClinVar, Apr 2023)[116]. Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline biallelic MUTYH mutation causes MUTYH-associated polyposis (also known as MYH-associated polyposis or MAP), an autosomal recessive condition characterized by multiple colorectal adenomas and increased lifetime risk of colorectal cancer (CRC)[105,117-119]. MAP accounts for approximately 0.7% of all CRC cases and 2% of early-onset CRC cases[105]. In contrast to CRC, the role of MUTYH mutation in the context of other cancer types is not well established[120-124]. Estimates for the prevalence of MAP in the general population range from 1:5,000-1:10,000[106]. Therefore, in the appropriate clinical context, germline testing of MUTYH is recommended.

GENE
PRDM1

ALTERATION
V10fs*10

HGVS VARIANT
NM_001198.3:c.29_30del (p.V10Gfs*10)

VARIANT CHROMOSOMAL POSITION
chr6:106534453-106534455

VARIANT ALLELE FREQUENCY (% VAF)
52.5%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no targeted therapies available to address genomic alterations in PRDM1.

FREQUENCY & PROGNOSIS

Inactivating somatic alterations of PRDM1 have been shown to occur in approximately one quarter of activated B-cell type diffuse large B-cell lymphomas (ABC-DLBCL) but not in other DLBCL subtypes[125]. In contrast to this tumor suppressor role in lymphoma, BLIMP-1 activity has been hypothesized to promote cell migration and invasion based on cell culture models of lung cancer[126].

FINDING SUMMARY

PRDM1 encodes the transcriptional repressor protein BLIMP-1, which antagonizes expression of beta-interferon, among other genes[127]. BLIMP-1 plays a key role in mediating terminal differentiation of myeloid cells and B-lymphocytes, in part through repression of c-MYC transcription[128].

GENE
SGK1

ALTERATION
loss exons 1-12

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

The PI3K inhibitor LY294002 has been reported to block SGK1 activity in a preclinical study[129]. Several SGK1 inhibitors[130-135] have been developed but are not suitable for clinical use. SGK1 and NDRG1 expression were reported to be increased in three PIK3CA-mutant breast cancer samples from patients who did not respond to treatment with the PI3K inhibitor BYL719 in combination with aromatase inhibitor[131]. Additionally, preclinical studies have reported that SGK1 expression confers resistance to BYL719 in breast cancer cells harboring PIK3CA activating mutations[131] and to the AKT inhibitors AZD5363 and MK2206 in breast cancer cells[136].

FREQUENCY & PROGNOSIS

SGK1 mutation has been observed in 6-16% of diffuse large B-cell lymphomas[137], 5/7 cases of variant nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), and 1/6 cases of typical NLPHL[138]. SGK1 amplification and mutation have rarely been observed in other tumor types (cBioPortal, COSMIC, 2023)[104,139-140]. Increased SGK1 expression has been reported in lung squamous cell carcinoma[141], endometrioid endometrial carcinoma[142], glioblastoma[143], and breast cancer[144].

FINDING SUMMARY

SGK1 encodes serum/glucocorticoid regulated kinase 1, which activates ion channels in response to cellular stress. SGK1 can be activated by PI3K-mTORC2 signaling[145] and can in turn activate mTORC1[131].

GENE
SMAD2

ALTERATION
loss exons 7-8

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no therapies that target the loss of SMAD2 or loss of TGF-beta signaling in cancer. Because TGF-beta can exert both tumor suppressor as well as pro-tumor effects, the development of therapies aimed at this pathway must be carefully considered for each patient. In preclinical studies, several novel small-molecule TGF-beta pathway inhibitors have been shown to reduce SMAD2 phosphorylation and tumor invasion in breast cancer cells and to increase survival in mouse xenograft models[146-147].

FREQUENCY & PROGNOSIS

SMAD2 mutations have been reported in various tumor types, including cutaneous squamous cell carcinoma (SCC; 6-10%)[148], colorectal adenocarcinoma (CRC; 3-7%)[43,149], endometrial cancers (2-5%)[40], stomach adenocarcinoma (2-3%)[150], lung SCC (1-2%)[151], and lung adenocarcinoma (1-2%)[152-155]. SMAD2 deletion, as well as loss of expression or phosphorylation (p-SMAD2), has been reported in several cancers[156-162] and has been correlated with poor prognosis in hepatocellular, gastric, breast, and colorectal cancer[157-161] but good prognosis in HNSCC[163-164].

FINDING SUMMARY

SMAD2 encodes an intracellular transducer that is activated by TGF-beta or activin to dimerize with SMAD4 and regulate transcription of TGF-beta or activin-activated genes[165-166]. SMAD2 alterations that disrupt the MH1 domain (amino acids 10-176), MH2 domain (amino acids 274-467), or critical phosphorylation sites are predicted to result in a loss of function[149,162,167-170].

GENE
TERT

ALTERATION
promoter -146C>T

HGVS VARIANT
NM_198253.2:c.-146C>T

VARIANT CHROMOSOMAL POSITION
chr5:1295250

VARIANT ALLELE FREQUENCY (% VAF)
17.3%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Therapeutic options for targeting tumors with TERT mutations are limited, although a variety of approaches have been investigated, including immunotherapies using TERT as a tumor-associated antigen and antisense oligonucleotide- or peptide-based therapies. TERT peptide vaccines showed limited anticancer efficacy in clinical trials[171]; however, in one preclinical study, the combination of a TERT peptide vaccine and anti-CTLA-4 therapy suppressed tumor growth[172]. A Phase 2 study of the TERT inhibitor imetelstat for patients with advanced non-small cell lung cancer reported no improvement in PFS or OS[173].

FREQUENCY & PROGNOSIS

TERT promoter mutations have been reported in 22-71% of melanoma cases, including 85% of metastatic melanomas, 66% of unknown primary melanomas, 32% (12/38) of conjunctival melanomas, 13.2% (7/53) of mucosal melanomas, 6% (2/32) of acral lentiginous melanomas, and 1/50 uveal melanomas[174-181]. TERT promoter mutations associate with increased TERT expression in melanoma[176-177,182]. Gains of the TERT locus have also been reported in 31.2% (5/16) of melanomas[65]. TERT promoter mutations or protein overexpression has been associated with poor clinico-pathological features, but not with impact on survival[174-175,182-183]. In addition, germline polymorphisms in TERT have been associated with risk of melanoma development[184-186].

FINDING SUMMARY

Telomerase reverse transcriptase (TERT, or hTERT) is a catalytic subunit of the telomerase complex, which is required to maintain appropriate chromosomal length[187]. Activation of TERT is a hallmark of cancer, being detected in up to 80-90% of malignancies and absent in quiescent cells[188-190]. Mutations within the promoter region of TERT that confer enhanced TERT promoter activity have been reported in two hotspots, located at -124 bp and -146 bp upstream of the transcriptional start site (also termed C228T and C250T, respectively)[176-177,181], as well as tandem mutations at positions –124/–125 bp and –138/–139 bp[177].

Trametinib

Assay findings association

NRAS
Q61R

AREAS OF THERAPEUTIC USE

Trametinib is a MEK inhibitor that is FDA approved as a monotherapy to treat patients with melanoma with BRAF V600E or V600K mutations. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical evidence, activating alterations of NRAS may predict sensitivity to MEK inhibitors[49-50,52,54,56-58,191-193] .

SUPPORTING DATA

One retrospective study of MEK inhibitors in NRAS-mutated melanoma reported an ORR of 23% (5/22) for pretreated patients with trametinib as a single agent[194], although efficacy was limited in a Phase 1 trial of advanced melanoma (0 PRs, 29% DCR [2/7])[195]. A real-world study of trametinib with or without anti-PD1 antibodies in immune checkpoint inhibitor (ICI)-resistant melanoma reported PRs for 5% (1/20) of patients with NRAS-mutated disease and a median OS of 6.5 months for the cohort overall (n=22)[196]. The combination of trametinib with paclitaxel resulted in PRs for 50% (4/8) of patients with melanoma harboring NRAS mutations[197].

Combination approaches pairing trametinib with other agents are also under investigation in NRAS-mutated melanoma. A Phase 2 study of trametinib and the BRAF/CRAF inhibitor LXH254 reported 1 PR and a DCR of 67% (16/24) for patients with ICI-resistant disease at the expansion dose[198], building on a Phase 1b trial reporting an ORR of 47% (7/15)[199]. A study reported responses for 25% (1/4) of patients with the combination of trametinib and ICIs[194]. As a monotherapy for patients with BRAF V600E/K-mutated metastatic melanoma, trametinib improved PFS (4.9 vs. 1.5 months, HR=0.54) and median OS (15.6 vs. 11.3 months, HR=0.84) compared with patients treated with chemotherapy[200]. In a Phase 1 study, 10% (4/40) of patients with BRAF-wildtype metastatic melanoma achieved a PR[195]. Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors[201], a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months[202].

Cobimetinib

Assay findings association

NRAS
Q61R

AREAS OF THERAPEUTIC USE

Cobimetinib is a MEK inhibitor that is FDA approved to treat patients with histiocytic neoplasms. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical evidence, activating alterations of NRAS may predict sensitivity to MEK inhibitors[49-50,52,54,56-58,191-193] .

SUPPORTING DATA

Significant clinical responses to various other MEK inhibitors have been documented in NRAS-mutant melanoma[57,62,191,203] . Patients with metastatic melanoma and NRAS mutations experienced PRs (26% [5/19]) and SDs (42% [8/19]) in response to cobimetinib combined with the RAF inhibitor belvarafenib[204]. A Phase 1 study of cobimetinib monotherapy in solid tumors reported 1% (1/97) CR and 6% (6/97) PR, all of which were achieved by patients with melanoma (6 with BRAF V600E)[205].

Patients with metastatic melanoma treated with cobimetinib combined with the RAF inhibitor belvarafenib experienced PRs for those with BRAF V600 mutations (33% [3/9]) and non-V600 mutations (50% [3/6])[204]. In the Phase 3 IMspire170 study, the combination of atezolizumab and cobimetinib did not improve median PFS (5.5 vs. 5.7 months), ORR (26% vs. 32%) or 6-month OS (88% vs. 87%) compared with pembrolizumab for patients with previously untreated BRAF V600 wildtype melanoma[206]. Similarly, the Phase 2 TRICOTEL trial for patients with BRAF wildtype melanoma with central nervous system metastases reported an intracranial ORR of 27% following combination treatment of atezolizumab and cobimetinib[207]. A Phase 1b study evaluating the combination of atezolizumab and cobimetinib for the treatment of patients with solid tumors reported an ORR of 41% (9/22) in patients with melanoma, regardless of BRAF status; the 12-month PFS and OS rates were 50% and 85%, respectively[208].

Selumetinib

Assay findings association

NRAS
Q61R

AREAS OF THERAPEUTIC USE

Selumetinib is a MEK inhibitor that is FDA approved to treat pediatric patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PNs). Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical evidence, activating alterations of NRAS may predict sensitivity to MEK inhibitors[49-50,52,54,56-58,191-193] .

SUPPORTING DATA

In a Phase 2 study for patients with metastatic melanoma, selumetinib monotherapy achieved an ORR of 5.8%; among patients with BRAF mutations, the ORR was 11% (5/45)[209]. In a Phase 2 trial of first-line treatment of BRAF-mutated metastatic melanoma, the addition of selumetinib to dacarbazine increased PFS compared to dacarbazine plus placebo (5.6 vs 3.0 months, HR=0.63) but did not significantly improve OS (13.9 vs 10.5 months, HR 0.93, p=0.39)[210]. In a Phase 2 trial for patients with BRAF wildtype advanced melanoma, the addition of selumetinib to docetaxel did not improve median PFS compared to docetaxel plus placebo (4.2 vs 3.9 months) and was associated with lower OS (9.5 months vs 11.4 months); NRAS mutation was associated with inferior OS (HR=0.78)[211].

NOTE Genomic alterations detected may be associated with activity of certain FDA approved drugs, however, the agents listed in this report may have varied evidence in the patient's tumor type.

NOTE Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. Or, visit https://www.foundationmedicine.com/genomic-testing#support-services.

GENE
NRAS

ALTERATION
Q61R

RATIONALE
Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF-MAPK-ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.

NCT04913285

PHASE 1

A Study to Evaluate KIN-2787 in Subjects With BRAF Mutation Positive Solid Tumors

TARGETS
BRAF, MEK

LOCATIONS: Taipei (Taiwan), Shanghai (China), Bengbu (China), Wuhan (China), Linyi (China), Gyeonggi-do (Korea, Republic of), Cheongju-si (Korea, Republic of), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Beijing (China)

NCT04803318

PHASE 2

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

TARGETS
mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK

LOCATIONS: Guangzhou (China)

NCT04985604

PHASE 1/2

DAY101 Monotherapy or in Combination With Other Therapies for Patients With Solid Tumors

TARGETS
BRAF, MEK

LOCATIONS: Busan (Korea, Republic of), Seoul (Korea, Republic of), Clayton (Australia), Edegem (Belgium), Oregon, Barcelona (Spain), Madrid (Spain), California, Colorado

NCT04835805

PHASE 1

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Atezolizumab in Patients With NRAS-mutant Advanced Melanoma.

TARGETS
MEK, RAFs, NRAS, PD-L1

LOCATIONS: Seoul (Korea, Republic of), Nedlands (Australia), Waratah (Australia), Melbourne (Australia), Oslo (Norway), Bergen (Norway), Berlin (Germany), Hamburg (Germany), Würzburg (Germany), Mannheim (Germany)

NCT03284502

PHASE 1

Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors

TARGETS
MEK, RAFs, NRAS

LOCATIONS: Hwasun (Korea, Republic of), Pusan (Korea, Republic of), Seongnam (Korea, Republic of), Seoul (Korea, Republic of), Goyang-si (Korea, Republic of)

NCT05580770

PHASE 1/2

Mirdametinib + BGB-3245 in Advanced Solid Tumors

TARGETS
BRAF, MEK

LOCATIONS: Waratah (Australia), Melbourne (Australia), California, Ohio, Massachusetts, Texas, Connecticut, Florida

NCT04551521

PHASE 2

CRAFT: The NCT-PMO-1602 Phase II Trial

TARGETS
PD-L1, AKTs, MEK, BRAF, ALK, RET, ERBB2

LOCATIONS: Lübeck (Germany), Würzburg (Germany), Mainz (Germany), Heidelberg (Germany), Tübingen (Germany)

NCT04892017

PHASE 1/2

A Safety, Tolerability and PK Study of DCC-3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors.

TARGETS
ULK1, ULK2, MEK

LOCATIONS: Oregon, Massachusetts, New York, Texas, Pennsylvania

NCT05340621

PHASE 1/2

OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

TARGETS
HDACs, MEK

LOCATIONS: California, Michigan, Massachusetts, New York, Tennessee, Virginia, Texas, Georgia, Florida

NCT04720976

PHASE 1/2

JAB-3312 Activity in Adult Patients With Advanced Solid Tumors

TARGETS
MEK, SHP2, PD-1, EGFR, KRAS

LOCATIONS: Utah, California, Arizona, Minnesota, Illinois, Michigan, Oklahoma, Missouri, Indiana, Connecticut

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

ALK
NM_004304.4: c.3820G>A
(p.A1274T)
chr2:29432668

DNMT3A
NM_022552.3: c.1010C>T
(p.S337L)
chr2:25470464

KDM5A
NM_001042603.1: c.806C>A
(p.T269N)
chr12:464388

LTK
NM_002344.5:
c.630_638dup
(p.G211_G213dup)
chr15:41804033

PARP1
NM_001618.3: c.1873G>A
(p.A625T)
chr1:226564877

PIK3C2G
NM_004570.4: c.263A>G
(p.E88G)
chr12:18435278 and
NM_004570.4: c.2941C>T
(p.R981C)
chr12:18656262

SNCAIP
NM_005460.2: c.1351G>A
(p.D451N)
chr5:121776378

SPEN
NM_015001.2: c.8399C>T
(p.A2800V)
chr1:16261134

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	*ACVR1B*	*AKT1*	*AKT2*	*AKT3*	*ALK*	*ALOX12B*	*AMER1 (FAM123B or WTX)*	
APC	*AR*	*ARAF*	*ARFRP1*	*ARID1A*	*ASXL1*	*ATM*	*ATR*	*ATRX*
AURKA	*AURKB*	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*
BCL6	*BCOR*	*BCORL1*	*BRAF*	*BRCA1*	*BRCA2*	*BRD4*	*BRIP1*	*BTG1*
BTG2	*BTK*	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*	*CCND1*	*CCND2*
CCND3	*CCNE1*	*CD22*	*CD274 (PD-L1)*	*CD70*	*CD79A*	*CD79B*	*CDC73*	*CDH1*
CDK12	*CDK4*	*CDK6*	*CDK8*	*CDKN1A*	*CDKN1B*	*CDKN2A*	*CDKN2B*	*CDKN2C*
CEBPA	*CHEK1*	*CHEK2*	*CIC*	*CREBBP*	*CRKL*	*CSF1R*	*CSF3R*	*CTCF*
CTNNA1	*CTNNB1*	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*	*DAXX*	*DDR1*	*DDR2*
DIS3	*DNMT3A*	*DOT1L*	*EED*	*EGFR*	*EMSY (C11orf30)*	*EP300*	*EPHA3*	*EPHB1*
EPHB4	*ERBB2*	*ERBB3*	*ERBB4*	*ERCC4*	*ERG*	*ERRFI1*	*ESR1*	*EZH2*
FANCA	*FANCC*	*FANCG*	*FANCL*	*FAS*	*FBXW7*	*FGF10*	*FGF12*	*FGF14*
FGF19	*FGF23*	*FGF3*	*FGF4*	*FGF6*	*FGFR1*	*FGFR2*	*FGFR3*	*FGFR4*
FH	*FLCN*	*FLT1*	*FLT3*	*FOXL2*	*FUBP1*	*GABRA6*	*GATA3*	*GATA4*
GATA6	*GID4 (C17orf39)*	*GNA11*	*GNA13*	*GNAQ*	*GNAS*	*GRM3*	*GSK3B*	*H3-3A (H3F3A)*
HDAC1	*HGF*	*HNF1A*	*HRAS*	*HSD3B1*	*ID3*	*IDH1*	*IDH2*	*IGF1R*
IKBKE	*IKZF1*	*INPP4B*	*IRF2*	*IRF4*	*IRS2*	*JAK1*	*JAK2*	*JAK3*
JUN	*KDM5A*	*KDM5C*	*KDM6A*	*KDR*	*KEAP1*	*KEL*	*KIT*	*KLHL6*
KMT2A (MLL)	*KMT2D (MLL2)*	*KRAS*	*LTK*	*LYN*	*MAF*	*MAP2K1 (MEK1)*	*MAP2K2 (MEK2)*	*MAP2K4*
MAP3K1	*MAP3K13*	*MAPK1*	*MCL1*	*MDM2*	*MDM4*	*MED12*	*MEF2B*	*MEN1*
MERTK	*MET*	*MITF*	*MKNK1*	*MLH1*	*MPL*	*MRE11 (MRE11A)*	*MSH2*	*MSH3*
MSH6	*MST1R*	*MTAP*	*MTOR*	*MUTYH*	*MYC*	*MYCL (MYCL1)*	*MYCN*	*MYD88*
NBN	*NF1*	*NF2*	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2*	*NOTCH3*
NPM1	*NRAS*	*NSD2 (WHSC1 or MMSET)*		*NSD3 (WHSC1L1)*	*NT5C2*	*NTRK1*	*NTRK2*	*NTRK3*
P2RY8	*PALB2*	*PARP1*	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1 (PD-1)*	*PDCD1LG2 (PD-L2)*
PDGFRA	*PDGFRB*	*PDK1*	*PIK3C2B*	*PIK3C2G*	*PIK3CA*	*PIK3CB*	*PIK3R1*	*PIM1*
PMS2	*POLD1*	*POLE*	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*
PRKN (PARK2)	*PTCH1*	*PTEN*	*PTPN11*	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*
RAD51B	*RAD51C*	*RAD51D*	*RAD52*	*RAD54L*	*RAF1*	*RARA*	*RB1*	*RBM10*
REL	*RET*	*RICTOR*	*RNF43*	*ROS1*	*RPTOR*	*SDHA*	*SDHB*	*SDHC*
SDHD	*SETD2*	*SF3B1*	*SGK1*	*SMAD2*	*SMAD4*	*SMARCA4*	*SMARCB1*	*SMO*
SNCAIP	*SOCS1*	*SOX2*	*SOX9*	*SPEN*	*SPOP*	*SRC*	*STAG2*	*STAT3*
STK11	*SUFU*	*SYK*	*TBX3*	*TEK*	*TENT5C (FAM46C)*		*TET2*	*TGFBR2*
TIPARP	*TNFAIP3*	*TNFRSF14*	*TP53*	*TSC1*	*TSC2*	*TYRO3*	*U2AF1*	*VEGFA*
VHL	*WT1*	*XPO1*	*XRCC2*	*ZNF217*	*ZNF703*			

DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	*BCL2*	*BCR*	*BRAF*	*BRCA1*	*BRCA2*	*CD74*	*EGFR*	*ETV4*
ETV5	*ETV6*	*EWSR1*	*EZR*	*FGFR1*	*FGFR2*	*FGFR3*	*KIT*	*KMT2A (MLL)*
MSH2	*MYB*	*MYC*	*NOTCH2*	*NTRK1*	*NTRK2*	*NUTM1*	*PDGFRA*	*RAF1*
RARA	*RET*	*ROS1*	*RSPO2*	*SDC4*	*SLC34A2*	*TERC**	*TERT***	*TMPRSS2*

*TERC is an NCRNA

**Promoter region of TERT is interrogated

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Homologous Recombination status
Loss of Heterozygosity (LOH) score
Microsatellite (MS) status
Tumor Mutational Burden (TMB)

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. CE

ABOUT FOUNDATIONONE CDX

FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details: www.rochefoundationmedicine.com/f1cdxtech.

INTENDED USE

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

TEST PRINCIPLE

FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes detection of alterations in a total of 324 genes.

Using an Illumina® HiSeq platform, hybrid capture–selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g.,gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

Diagnostic Significance

FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

Qualified Alteration Calls (Equivocal and Subclonal)

An alteration denoted as "amplification – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for *ERBB2* and six (6) for all other genes. Conversely, an alteration denoted as "loss – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical methodology has identified as being present in <10% of the assayed tumor DNA.

Ranking of Therapies and Clinical Trials

Ranking of Therapies in Summary Table
Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials
Pediatric trial qualification → Geographical proximity → Later trial phase.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Limitations

1. In the fraction-based MSI algorithm, a tumor specimen will be categorized as MSI-H, MSS, or MS-Equivocal according to the fraction of microsatellite loci determined to be altered or unstable (i.e., the fraction unstable loci score). In the F1CDx assay, MSI is evaluated based on a genome-wide analysis across >2000 microsatellite loci. For a given microsatellite locus, non-somatic alleles are discarded, and the microsatellite is categorized as unstable if remaining alleles differ from the reference genome. The final fraction unstable loci score is calculated as the number of unstable microsatellite loci divided by the number of evaluable microsatellite loci. The MSI-H and MSS cut-off thresholds were determined by

analytical concordance to a PCR comparator assay using a pan-tumor FFPE tissue sample set. Patients with results categorized as "MS-Stable" with median exon coverage <300X, "MS-Equivocal," or "Cannot Be Determined" should receive confirmatory testing using a validated orthogonal (alternative) method.

2. TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.
3. Homologous Recombination status may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas (Coleman et al., 2017; 28916367). Samples with deleterious *BRCA1/2* alteration and/or Loss of Heterozygosity (LOH) score ≥ 16% will be reported as "HRD Positive" and samples with absence of these findings will be reported as "HRD Not Detected," agnostic of potential secondary *BRCA1/2* reversion alterations. Certain potentially deleterious missense or small in-frame deletions in *BRCA1/2* may not be classified as deleterious and, in the absence of an elevated LOH profile, samples with such mutations may be classified as "HRD Not Detected." A result of "HRD Not Detected" does not rule out the presence of a *BRCA1/2* alteration or an elevated LOH profile outside the assay performance characteristic limitations.
4. The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH. Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.
5. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.
6. Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine whether the patient is a candidate for biopsy.
7. Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an *ERBB2* amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive, and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of *ERBB2* copy number 4 in breast cancer is estimated to be approximately 2%. Multiple references listed in https://www.mycancergenome.org/content/disease/breast-cancer/ERBB2/238/ report the frequency of HER2 overexpression as 20% in breast cancer. Based on the F1CDx HER2 CDx concordance study, approximately 10% of HER2 amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANT ALLELE FREQUENCY

Variant Allele Frequency (VAF) represents the fraction of sequencing reads in which the variant is observed. This attribute is not taken into account for therapy inclusion, clinical trial matching, or interpretive content. Caution is recommended in interpreting VAF to indicate the potential germline or somatic origin of an alteration, recognizing that tumor fraction and tumor ploidy of samples may vary.

Precision of VAF for base substitutions and indels

BASE SUBSTITUTIONS	%CV*
Repeatability	5.11 - 10.40
Reproducibility	5.95 - 12.31
INDELS	**%CV***
Repeatability	6.29 - 10.00
Reproducibility	7.33 - 11.71

**Interquartile Range = 1st Quartile to 3rd Quartile*

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >10%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's

tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, CBL, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2,* and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne CDx.

TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

REFERENCE SEQUENCE INFORMATION

Sequence data is mapped to the human genome, Genome Reference Consortium Human Build 37 (GRCh37), also known as hg19.

MR Suite Version (RG) 7.9.0

The median exon coverage for this sample is 819x

1. Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179
2. Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250
3. Lal N, et al. Oncoimmunology (2015) pmid: 25949894
4. Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255
5. Ayers et al., 2016; ASCO-SITC Abstract P60
6. Kubeček O, et al. Melanoma Res. (2016) pmid: 27623135
7. Kubecek O, et al. Med. Hypotheses (2016) pmid: 27372860
8. Peris K, et al. J. Invest. Dermatol. (1995) pmid: 7561170
9. Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942
10. You JF, et al. Br. J. Cancer (2010) pmid: 21081928
11. Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249
12. Boland CR, et al. Cancer Res. (1998) pmid: 9823339
13. Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785
14. Boland CR, et al. Gastroenterology (2010) pmid: 20420947
15. Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254
16. Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386
17. Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947
18. Cristescu R, et al. Science (2018) pmid: 30309915
19. Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829
20. Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845
21. Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128
22. Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394
23. Rozeman EA, et al. Nat Med (2021) pmid: 33558721
24. Sharma P, et al. Cancer Cell (2020) pmid: 32916128
25. Johnson DB, et al. Cancer Immunol Res (2016) pmid: 27671167
26. Ning B, et al. Front Pharmacol (2022) pmid: 35355708
27. Hodi et al., 2019; AACR abstract CT037
28. Liu L, et al. Clin. Cancer Res. (2019) pmid: 31515453
29. Chalmers ZR, et al. Genome Med (2017) pmid: 28420421
30. Alexandrov LB, et al. Nature (2013) pmid: 23945592
31. Shain AH, et al. Nat. Genet. (2015) pmid: 26343386
32. Madore J, et al. Clin. Cancer Res. (2016) pmid: 26960397
33. Shain AH, et al. N. Engl. J. Med. (2015) pmid: 26559571
34. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
35. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
36. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
37. Rizvi NA, et al. Science (2015) pmid: 25765070
38. Johnson BE, et al. Science (2014) pmid: 24336570
39. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
40. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
41. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
42. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
43. Nature (2012) pmid: 22810696
44. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
45. Eroglu Z, et al. Nature (2018) pmid: 29320474
46. Shin DS, et al. Cancer Discov (2017) pmid: 27903500
47. Riaz N, et al. Cell (2017) pmid: 29033130
48. Lancet Oncol. (2020) pmid: 32919529
49. Slosberg ED, et al. Oncotarget (2018) pmid: 29765547
50. Ravandi F, et al. Blood Cancer J (2015) pmid: 26657199
51. Maiti A, et al. Clin Lymphoma Myeloma Leuk (2019) pmid: 30635233
52. Khanna V, et al. Cureus (2015) pmid: 26870618
53. Heuck CJ, et al. Leukemia (2016) pmid: 26228812
54. Abdel-Wahab O, et al. Cancer Discov (2014) pmid: 24589925
55. Holkova B, et al. Clin. Cancer Res. (2016) pmid: 26446942
56. Dummer R, et al. Lancet Oncol. (2017) pmid: 28284557
57. Ascierto PA, et al. Lancet Oncol. (2013) pmid: 23414587
58. van Herpen CML, et al. Oncotarget (2019) pmid: 30956763
59. Sullivan RJ, et al. Cancer Discov (2018) pmid: 29247021
60. Yen I, et al. Nature (2021) pmid: 33953400
61. van Not OJ, et al. JCO Precis Oncol (2022) pmid: 36130145
62. Martinez-Garcia M, et al. Clin. Cancer Res. (2012) pmid: 22761467
63. Lee JH, et al. Br. J. Dermatol. (2011) pmid: 21166657
64. Xia J, et al. Mol. Cancer Ther. (2014) pmid: 24755198
65. Puig-Butillé JA, et al. Exp. Dermatol. (2013) pmid: 23362874
66. J. Invest. Dermatol. (2010) pmid: 19571822
67. Pylayeva-Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244
68. Monzon JG, et al. Onco Targets Ther (2012) pmid: 22419879
69. Platz A, et al. Mol Oncol (2008) pmid: 19383313
70. Omholt K, et al. Clin. Cancer Res. (2002) pmid: 12429636
71. Ekedahl H, et al. Br. J. Dermatol. (2013) pmid: 23855428
72. Dutton-Regester K, et al. Pigment Cell Melanoma Res (2013) pmid: 23890154
73. Jakob JA, et al. Cancer (2012) pmid: 22180178
74. Zebary A, et al. J. Dermatol. Sci. (2013) pmid: 23993026
75. Griewank KG, et al. Clin. Cancer Res. (2013) pmid: 23633454
76. Uhara H, et al. Int. J. Clin. Oncol. (2014) pmid: 23739925
77. Wong CW, et al. J. Clin. Pathol. (2005) pmid: 15917418
78. Aulmann S, et al. Mod. Pathol. (2014) pmid: 24603591
79. Wang HY, et al. Oncologist (2019) pmid: 31578274
80. Devitt B, et al. Pigment Cell Melanoma Res (2011) pmid: 21615881
81. Birkeland E, et al. Clin. Exp. Metastasis (2013) pmid: 23673558
82. Mann GJ, et al. J. Invest. Dermatol. (2013) pmid: 22931913
83. Si L, et al. Eur. J. Cancer (2012) pmid: 21788131
84. Rutkowski P, et al. Oncol Lett (2014) pmid: 24959217
85. Carlino MS, et al. Br. J. Cancer (2014) pmid: 24918823
86. Egberts F, et al. Ann. Oncol. (2014) pmid: 24276025
87. Wu S, et al. Cancer Causes Control (2014) pmid: 25048604
88. Buhrman G, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20194776
89. Cirstea IC, et al. Nat. Genet. (2010) pmid: 19966803
90. Sci. STKE (2004) pmid: 15367757
91. Edkins S, et al. Cancer Biol. Ther. (2006) pmid: 16969076
92. Feig LA, et al. Mol. Cell. Biol. (1988) pmid: 3043178
93. Janakiraman M, et al. Cancer Res. (2010) pmid: 20570890
94. Lukman S, et al. PLoS Comput. Biol. (2010) pmid: 20838576
95. Prior IA, et al. Cancer Res. (2012) pmid: 22589270
96. Privé GG, et al. Proc. Natl. Acad. Sci. U.S.A. (1992) pmid: 1565661
97. Runtuwene V, et al. Dis Model Mech (2011) pmid: 21263000
98. Scheffzek K, et al. Science (1997) pmid: 9219684
99. Smith G, et al. Br. J. Cancer (2010) pmid: 20147967
100. Tyner JW, et al. Blood (2009) pmid: 19075190
101. Gremer L, et al. Hum. Mutat. (2011) pmid: 20949621
102. Altmüller F, et al. Eur J Hum Genet (2017) pmid: 28594414
103. Hiippala A, et al. Am. J. Med. Genet. A (2016) pmid: 26888048
104. Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878
105. Hegde M, et al. Genet. Med. (2014) pmid: 24310308
106. Aretz S, et al. Eur. J. Hum. Genet. (2013) pmid: 22872101
107. Win AK, et al. Gastroenterology (2014) pmid: 24444654
108. Lubbe SJ, et al. J. Clin. Oncol. (2009) pmid: 19620482
109. Jones N, et al. Gastroenterology (2009) pmid: 19394335
110. Nielsen M, et al. J. Natl. Cancer Inst. (2010) pmid: 21044966
111. David SS, et al. Nature (2007) pmid: 17581577
112. Molatore S, et al. Hum. Mutat. (2010) pmid: 19953527
113. Kundu S, et al. DNA Repair (Amst.) (2009) pmid: 19836313
114. D'Agostino VG, et al. DNA Repair (Amst.) (2010) pmid: 20418187
115. Ali M, et al. Gastroenterology (2008) pmid: 18534194
116. Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669
117. Sampson JR, et al. Lancet (2003) pmid: 12853198
118. Sieber OM, et al. N. Engl. J. Med. (2003) pmid: 12606733
119. Al-Tassan N, et al. Nat. Genet. (2002) pmid: 11818965
120. Rennert G, et al. Cancer (2012) pmid: 21952991
121. Zhang Y, et al. Cancer Epidemiol. Biomarkers Prev. (2006) pmid: 16492928
122. von der Thüsen JH, et al. J. Clin. Oncol. (2011) pmid: 21189386
123. Casper M, et al. Fam. Cancer (2014) pmid: 24420788
124. Smith LM, et al. Pancreatology (2009) pmid: 20110747
125. Pasqualucci L, et al. J. Exp. Med. (2006) pmid: 16492805
126. Yu Z, et al. PLoS ONE (2012) pmid: 22438909
127. Keller AD, et al. Genes Dev. (1991) pmid: 1851123
128. Chang DH, et al. Nat. Immunol. (2000) pmid: 11248811
129. Park J, et al. EMBO J. (1999) pmid: 10357815
130. Ackermann TF, et al. Cell. Physiol. Biochem. (2011) pmid: 21865856
131. Castel P, et al. Cancer Cell (2016) pmid: 27451907
132. Halland N, et al. ACS Med Chem Lett (2015) pmid: 25589934
133. Mansley MK, et al. Br. J. Pharmacol. (2010) pmid: 20880397
134. O'Neill D, et al. Oncotarget (2015) pmid: 26267320
135. Sherk AB, et al. Cancer Res. (2008) pmid: 18794135
136. Sommer EM, et al. Biochem. J. (2013) pmid: 23581296
137. Lohr JG, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22343534
138. Hartmann S, et al. Leukemia (2016) pmid: 26658840
139. Cerami E, et al. Cancer Discov (2012) pmid: 22588877
140. Gao J, et al. Sci Signal (2013) pmid: 23550210
141. Abbruzzese C, et al. J. Exp. Clin. Cancer Res. (2012) pmid: 22240294
142. Conza D, et al. J. Cell. Physiol. (2017) pmid: 28177128
143. Talarico C, et al. Oncotarget (2016) pmid: 26908461
144. Sahoo S, et al. Eur. J. Cancer (2005) pmid: 16246546
145. García-Martínez JM, et al. Biochem. J. (2008) pmid: 18925875

146. Ehata S, et al. Cancer Sci. (2007) pmid: 17129361
147. Rausch MP, et al. Anticancer Res. (2009) pmid: 19528470
148. Li YY, et al. Clin. Cancer Res. (2015) pmid: 25589618
149. Fleming NI, et al. Cancer Res. (2013) pmid: 23139211
150. Nature (2014) pmid: 25079317
151. Nature (2012) pmid: 22960745
152. Nature (2014) pmid: 25079552
153. Imielinski M, et al. Cell (2012) pmid: 22980975
154. Uchida K, et al. Cancer Res. (1996) pmid: 8971158
155. Ding L, et al. Nature (2008) pmid: 18948947
156. Boulay JL, et al. Genes Chromosomes Cancer (2001) pmid: 11391794
157. Xie W, et al. Cancer J () pmid: 12967141
158. Koumoundourou D, et al. Anticancer Res. () pmid: 17695423
159. Xie W, et al. Cancer Res. (2002) pmid: 11809701
160. Liapis G, et al. APMIS (2007) pmid: 17295676
161. Wu SK, et al. World J. Gastroenterol. (2007) pmid: 17729405
162. Macías-Silva M, et al. Cell (1996) pmid: 8980228
163. Xie W, et al. Head Neck (2013) pmid: 22275186
164. Mangone FR, et al. Mol. Cancer (2010) pmid: 20462450
165. Lebrun JJ, et al. Mol. Endocrinol. (1999) pmid: 9892009
166. Lin X, et al. Cell (2006) pmid: 16751101
167. Funaba M, et al. J. Biol. Chem. (2002) pmid: 12193595
168. Massagué J, et al. Genes Dev. (2005) pmid: 16322555
169. Matsuzaki K, et al. Cancer Res. (2009) pmid: 19531654
170. Wu Y, et al. PLoS ONE (2012) pmid: 22539990
171. Nat Rev Clin Oncol (2017) pmid: 27245281
172. Duperret EK, et al. Mol Ther (2018) pmid: 29249395
173. Chiappori AA, et al. Ann Oncol (2015) pmid: 25467017
174. Pópulo H, et al. J. Invest. Dermatol. (2014) pmid: 24691053
175. Egberts F, et al. Melanoma Res. (2014) pmid: 24463461
176. Huang FW, et al. Science (2013) pmid: 23348506
177. Horn S, et al. Science (2013) pmid: 23348503
178. Liau JY, et al. J. Cutan. Pathol. (2014) pmid: 24588324
179. Scott GA, et al. Mod. Pathol. (2014) pmid: 24030752
180. Griewank KG, et al. Br. J. Cancer (2013) pmid: 23799844
181. Vinagre J, et al. Nat Commun (2013) pmid: 23887589
182. Heidenreich B, et al. Nat Commun (2014) pmid: 24569790
183. Zygouris P, et al. J BUON () pmid: 18067210
184. Law MH, et al. J. Invest. Dermatol. (2012) pmid: 21993562
185. Yin J, et al. PLoS ONE (2012) pmid: 23226346
186. Nan H, et al. Hum. Genet. (2011) pmid: 21116649
187. Shay JW, et al. Semin. Cancer Biol. (2011) pmid: 22015685
188. Shay JW, et al. Eur. J. Cancer (1997) pmid: 9282118
189. Kim NW, et al. Science (1994) pmid: 7605428
190. Hanahan D, et al. Cell (2000) pmid: 10647931
191. Zimmer L, et al. Clin. Cancer Res. (2014) pmid: 24947927
192. Van Herpen et al., 2014; ESMO Abstract LBA35
193. Goldinger SM, et al. Br. J. Dermatol. (2020) pmid: 31436845
194. Salzmann M, et al. Eur J Cancer (2022) pmid: 35272084
195. Falchook GS, et al. Lancet Oncol. (2012) pmid: 22805292
196. Pigné T, et al. Melanoma Res (2023) pmid: 36919691
197. Coupe N, et al. Eur. J. Cancer (2015) pmid: 25542057
198. Lebbe et al., 2022; ESMO Abstract LBA40
199. de Braud et al., 2022; AACR Abstract CT197
200. Robert C, et al. Eur J Cancer (2019) pmid: 30690294
201. Tolcher AW, et al. Ann. Oncol. (2015) pmid: 25344362
202. Patterson et al., 2018; AACR Abstract 3891
203. Adjei AA, et al. J. Clin. Oncol. (2008) pmid: 18390968
204. Kim et al., 2021; ESMO Abstract 529P
205. Rosen LS, et al. Invest New Drugs (2016) pmid: 27424159
206. Arance et al., 2019; ESMO Abstract LBA69
207. Dummer R, et al. Lancet Oncol (2022) pmid: 35940183
208. Hellmann MD, et al. Ann. Oncol. (2019) pmid: 30918950
209. Kirkwood JM, et al. Clin. Cancer Res. (2012) pmid: 22048237
210. Robert C, et al. Lancet Oncol. (2013) pmid: 23735514
211. Gupta A, et al. Ann. Oncol. (2014) pmid: 24567366